SCHEMBL5055145

SCHEMBL5055145

CCCCOc1ccc(C(=O)CBr)cc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.65
GSK3B P49841 1/20 0.62
MMP1 P03956 1/20 0.60
THRB P10828 4/20 0.60
THRA P10827 2/20 0.60
TP53 P04637 1/20 0.60
TSHR P16473 1/20 0.60
PLA2G4B P0C869 2/20 0.58
RARB P10826 3/20 0.55
ALDH1A1 P00352 3/20 0.55
LMNA P02545 2/20 0.55
CYP1A2 P05177 1/20 0.55
CHRM2 P08172 1/20 0.55
CHRM4 P08173 1/20 0.55
CHRM5 P08912 1/20 0.55
CYP2D6 P10635 1/20 0.55
CYP2C9 P11712 1/20 0.55
ADRA2C P18825 1/20 0.55
DRD4 P21917 1/20 0.55
ACHE P22303 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2356907 0.97 TP53 (0.66) L3MBTL1GSK3BMMP1THRBTHRA
SCHEMBL7861984 0.95 TP53 (0.69) L3MBTL1GSK3BTHRBTHRATP53
SCHEMBL14644865 0.95 TP53 (0.69) L3MBTL1GSK3BTHRBTHRATP53
SCHEMBL7861703 0.95 TP53 (0.69) L3MBTL1GSK3BTHRBTHRATP53
SCHEMBL8591116 0.95 TP53 (0.69) L3MBTL1GSK3BTHRBTHRATP53
SCHEMBL4629110 0.95 TP53 (0.69) L3MBTL1GSK3BTHRBTHRATP53
SCHEMBL1437711 0.95 TP53 (0.69) L3MBTL1GSK3BTHRBTHRATP53
SCHEMBL5057170 0.93 L3MBTL1 (0.70) L3MBTL1GSK3BMMP1THRBTHRA
SCHEMBL7371927 0.92 RARB (0.68) L3MBTL1GSK3BMMP1THRBTHRA
SCHEMBL8673568 0.89 PLA2G4B (0.55) L3MBTL1GSK3BMMP1THRBTHRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-3976656-A 1,4-Bis(5-p-n-butoxyphenyloxazol-2-yl)benzene and the preparaion thereof THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) 1976-08-24 US claimed
US-12024519-B2 Fused ring derivative having MGAT-2 inhibitory activity SHIONOGI & CO., LTD. (JP) 2024-07-02 US disclosed
US-20160166560-A1 Urea Compounds and Their Use as FAAH Enzyme Inhibitors BIAL-PORTELA & CA, S.A. (PT) 2016-06-16 US disclosed
US-20150344467-A1 5- AND 6-MEMBERED HETEROCYCLIC COMPOUNDS FMR LLC 2015-12-03 US disclosed
WO-2015016728-A1 UREA COMPOUNDS AND THEIR USE AS FAAH ENZYME INHIBITORS BIAL - PORTELA & Cª, S.A. (PT) 2015-02-05 WO disclosed
US-20140038965-A1 5- AND 6-MEMBERED HETEROCYCLIC COMPOUNDS ENVIVO PHARMACEUTICALS, INC. (US) 2014-02-06 US disclosed
US-8481534-B2 5- and 6-membered heterocyclic compounds ENVIVO PHARMACEUTICALS, INC. (US) 2013-07-09 US disclosed
US-8277777-B2 Compound having affinity for amyloid NIHON MEDI-PHYSICS CO., LTD. (JP) 2012-10-02 US disclosed
US-20110183976-A1 5- AND 6-MEMBERED HETEROCYCLIC COMPOUNDS FMR LLC 2011-07-28 US disclosed
US-20100092387-A1 Novel Compound Having Affinity For Amyloid NIHON MEDI-PHYSICS CO., LTD. (JP) 2010-04-15 US disclosed
EP-0736509-B1 Processes for preparing optically active alcohols and optically active amines SUMITOMO CHEMICAL CO (JP) 2001-11-14 EP disclosed
US-6156940-A Process for producing optically active carbinols SUMIKA FINE CHEMICALS COMPANY, LIMITED (JP) 2000-12-05 US disclosed
US-6025531-A REACTING A PROCHIRAL KETONE WITH A MIXTURE BORON-CONTAINING COMPOUNDS HAVING A BORANE REACTION PRODUCT FROM OPTICALLY ACTIVE BETA-AMINOALCOHOL AND A BORON HYDRIDE OR A METAL BOROHYDRIDE, AND AN OPTICALLY ACTIVE OXAZABOROLIDINE SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2000-02-15 US disclosed
EP-0713848-B1 Process for producing optically active carbinols SUMIKA FINE CHEMICALS COMPANY (JP) 1999-09-08 EP disclosed
US-5831132-A REDUCING AGENT FROM BORANES AND AMINO ALCOHOLS SUMIKA FINE CHEMICALS COMPANY, LTD. (JP) 1998-11-03 US disclosed
US-5801280-A Processes for preparing optically active alcohols and optically active amines SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1998-09-01 US disclosed
EP-0736509-A2 Processes for preparing optically active alcohols and optically active amines SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1996-10-09 EP disclosed
EP-0713848-A1 Process for producing optically active carbinols SUMIKA FINE CHEMICALS Company, Limited (JP) 1996-05-29 EP disclosed
US-4033978-A Thiacycl[2.2.2]azine carboxylic acids SYNTEX (U.S.A.) INC. (US) 1977-07-05 US disclosed
US-3976656-A 1,4-Bis(5-p-n-butoxyphenyloxazol-2-yl)benzene and the preparaion thereof THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) 1976-08-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150344467-A1 5- AND 6-MEMBERED HETEROCYCLIC COMPOUNDS PDE7A, ACHE, PDE5A L3MBTL1 2697/4885GSK3B 905/4885MMP1 1288/4885
US-20160166560-A1 Urea Compounds and Their Use as FAAH Enzyme Inhibitors FAAH, FAAH2, HRH2 L3MBTL1 4173/4885GSK3B 4753/4885MMP1 1408/4885
US-20140038965-A1 5- AND 6-MEMBERED HETEROCYCLIC COMPOUNDS PDE7A, ACHE, PDE5A L3MBTL1 2697/4885GSK3B 905/4885MMP1 1288/4885
US-20110183976-A1 5- AND 6-MEMBERED HETEROCYCLIC COMPOUNDS ACHE, PDE7A, PDE5A L3MBTL1 2678/4885GSK3B 934/4885MMP1 1331/4885
US-20100092387-A1 Novel Compound Having Affinity For Amyloid APP, SLC43A1, APBA1 L3MBTL1 395/4885GSK3B 3265/4885MMP1 2918/4885
US-12024519-B2 Fused ring derivative having MGAT-2 inhibitory activity MGAT2, MGAT1, ACAT2 L3MBTL1 704/4885GSK3B 1437/4885MMP1 4169/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.